

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Effectiveness of omega-3 fatty acid administration on completion rate of adjuvant chemotherapy for biliary tract cancer: study protocol for a single-center, open-label, single-arm, historically controlled study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029915
Article Type:	Protocol
Date Submitted by the Author:	19-Feb-2019
Complete List of Authors:	Ueno, Kimihiko; Kobe University, Hepato-Biliary-Pancreatic Surgery Ajiki, Tetsuo; Kobe University Graduate School of Medicine, Hepato-Biliary-Pancreatic Surgery Tsugawa, Daisuke; Kobe University, Hepato-Biliary-Pancreatic Surgery Akita, Masayuki; Kobe University, Hepato-Biliary-Pancreatic Surgery Hashimoto, Yu; Kobe university, Hepato-Biliary-Pancreatic Surgery Awazu, Masahide; Kobe University, Hepato-Biliary-Surgery Mukubo, Hideyo; Kobe University, Hepato-Biliary-Pancreatic Surgery Komatsu, Shohei; Kobe University, Hepato-Biliary-Surgery Kuramitsu, Kaori; Kobe University, Hepato-Biliary-Surgery Terai, Sachio; Kobe University Graduate School of Medicine, Surgery Tanaka, Motofumi; Kobe University, Hepato-Biliary-Pancreatic Surgery Toyama, Hirochika; Kobe University, Hepato-Biliary-Pancreatic Surgery Kido, Masahiro; Kobe University, Hepato-Biliary-Surgery Fukumoto, Takumi; Kobe University, Hepato-Biliary-Pancreatic Surgery
Keywords:	Biliary tract cancer, CHEMOTHERAPY, adjuvant, omega 3 fatty acid, S1

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Effectiveness of omega-3 fatty acid administration on completion rate of adjuvant**  
5  
6  
7 **chemotherapy for biliary tract cancer: study protocol for a single-center, open-label,**  
8  
9  
10 **single-arm, historically controlled study**  
11  
12  
13  
14  
15

16 Kimihiko Ueno Tetsuo Ajiki Daisuke Tsugawa Masayuki Akita Yu Hashimoto

17  
18  
19 Masahide Awazu Hideyo Mukubo Shohei Komatsu Kaori Kuramitsu Sachio Terai

20  
21  
22 Motofumi Tanaka Hirichika Toyama Masahiro Kido Takumi Fukumoto  
23  
24  
25  
26

27 Department of Hepato-Biliary-Pancreatic surgery Kobe University Graduate School of  
28  
29 Medicine; Kobe-city Hyogo Japan  
30  
31  
32  
33

34 **Corresponding Author**

35  
36 Kimihiko Ueno

37  
38  
39 7-5-2 Kusunoki-cho Cyuo-ku Kobe-city Hyogo-pref Japan  
40  
41

42 E-mail : [kueno.rhmn@gmail.com](mailto:kueno.rhmn@gmail.com)

43  
44  
45 TEL : 078-382-6302 FAX : 078-382-6307  
46  
47  
48

49 **Key Word** Biliary Tract Cancer, Chemotherapy, Adjuvant, Omega-3 fatty acid, S-1  
50  
51  
52  
53

54 **Word count:** 3,248 words  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction:** Multimodal treatment prolongs the survival of biliary tract cancer patients.

However, there are not so many choices of chemotherapy, and to complete each chemotherapy session is important. Adjuvant chemotherapy has been tried for biliary tract cancer, but the completion rate of 75% this is not enough. Body weight loss and cholangitis are reasons for interruption of chemotherapy. Previous reports suggested that nutritional intervention containing omega-3 fatty acid maintained bodyweight and improved the completion rate of chemotherapy. Moreover, omega-3 fatty acid has an anti-inflammatory effect. Omega-3 fatty acid is expected to improve the completion rate of adjuvant chemotherapy in biliary tract cancer patients. The aim of this study is to evaluate the effectiveness of omega-3 fatty acid for patients planning adjuvant chemotherapy for biliary tract cancer.

**Method and analysis:** This study is a single center, open-label, single-arm, historically controlled study with a planned enrollment of 55 participants. Protocol treatment consists of four courses of S-1 adjuvant chemotherapy and oral omega-3 fatty acid pharmaceutical adjuvant (LOTRIGA 2g<sup>®</sup> (Takeda pharmaceutical Co. Ltd)) which include 2g of omega-3 fatty acid from day one until day168 of the treatment period. The primary endpoint is the completion rate of four total courses of S-1. The secondary endpoints are post-operative

1  
2  
3  
4 cholangitis, time to recurrence or distant metastasis, changes of nutritional index, changes of  
5  
6  
7 lymphocyte blast transformation test induced by phytohemagglutinin, and concanavalin A  
8  
9  
10 and diamine oxidase serum activity during adjuvant chemotherapy. All adverse events will be  
11  
12  
13 evaluated.

14  
15  
16 **Ethics and dissemination:** This protocol was approved by the Institutional Review Board of  
17  
18 Kobe University Hospital. The findings from this study will be presented at national and  
19  
20 international conferences and published in peer-reviewed journals.  
21  
22  
23

24  
25 **Trial registration number:** UMIN Clinical Trials Registry UMIN000031247.  
26  
27  
28  
29

## 30 31 **ARTICLE SUMMARY**

### 32 33 **Strengths and limitations of this study**

34  
35 # This study investigates the effectiveness of omega-3 fatty acid on the completion rate of  
36  
37 adjuvant chemotherapy for biliary tract cancer.  
38  
39

40  
41 # This study is well planned for the selection of participants because biliary tract cancer  
42  
43 include four different cancers depends on its' location.  
44  
45

46  
47 # A main limitation of this study is related to it being a historically controlled study, which  
48  
49 includes some bias.  
50  
51

52  
53 # Because the primary endpoint of this study is the completion rate of chemotherapy, not the  
54  
55 prognosis of patients, the effect on survival can only be interpreted as a guide.  
56  
57  
58  
59  
60

## INTRODUCTION

While surgical resection is a definitive treatment for biliary tract cancer, the 5-year survival rate is about 30-50%<sup>1</sup>, which is lower than that of other gastrointestinal cancers. Because of the limitation of surgical resection, multimodal treatment is expected to improve rates of survival<sup>2</sup>. In spite of the importance of adjuvant chemotherapy, its start and continuation is difficult after biliary surgery. This means that biliary surgery such as liver resection and pancreaticoduodenectomy is very invasive, and easily results in delayed recovery from surgery as well as bacterial translocation which arises from malnutrition and immunological deterioration. Uncontrolled bacterial translocation causes cholangitis, and cholangitis interrupts chemotherapy. A feasibility study of S-1 adjuvant chemotherapy for biliary tract cancer showed that 75.8% of biliary tract cancer patients completed 24 weeks' protocol<sup>3</sup>. The main causes of discontinuation were adverse events and detection of relapse. This rate is similar to that for gastric (78%)<sup>4</sup> and pancreatic (72%) cancers<sup>5</sup>. Biliary tract cancer has only a few choices of chemotherapy; therefore completing each chemotherapy session is required. Improvement in the completion rate of adjuvant chemotherapy is an important result for biliary tract cancer.

Previous reports suggested that body weight loss is one cause of interruption of adjuvant chemotherapy<sup>6</sup>. Nutritional intervention containing omega-3 fatty acid maintained

1  
2  
3  
4 body weight <sup>7 8</sup> and improved the completion rate of adjuvant chemotherapy<sup>7</sup>. Omega-3 fatty  
5  
6  
7 acid are metabolized to lipid mediators, and these mediators evoke anti-inflammatory and  
8  
9  
10 novel pro-resolving mechanisms as well as enhance microbial clearance <sup>9</sup>. In addition, enteral  
11  
12  
13 immunonutrition using omega-3 fatty acid reduces bacterial translocation and atrophy of  
14  
15  
16 intestinal mucosal villi in rats with obstructive jaundice. Omega-3 fatty acid are expected to  
17  
18  
19 be a nutritional intervention for patients after biliary surgery in terms of maintenance of body  
20  
21  
22 weight and immunity. Moreover, as previous reports suggested an anti-tumor effect of  
23  
24  
25 omega-3 fatty acid <sup>10-13</sup>, this is an appropriate drug for cancer patients.  
26  
27

28 The aim of this study is to evaluate the efficacy of omega-3 fatty acid on adjuvant  
29  
30  
31 chemotherapy. Because patients to whom chemotherapy was administered tend to reduce  
32  
33  
34 dietary intake, and patients after biliary surgery are prone to cholangitis, omega-3 fatty acid is  
35  
36  
37 used in this study for nutritional support and anti-inflammatory treatment. We conduct this  
38  
39  
40 study with the estimation that omega-3 fatty acid improves tolerance for adjuvant  
41  
42  
43 chemotherapy after biliary surgery from the point of view of body weight and anti-  
44  
45  
46 cholangitis.  
47  
48  
49  
50  
51

## 52 **METHODS AND ANALYSIS**

### 55 **Study design**

58 This study is a single-center, open-label, single-arm, historically controlled study of patients  
59  
60

1  
2  
3  
4 who are administered S-1 after surgical resection of biliary tract cancer. The aim of this study  
5  
6  
7 is to examine the improvement of completion rates of adjuvant chemotherapy by  
8  
9  
10 administration of omega-3 fatty acid. All participants are scheduled to receive administration  
11  
12  
13 of four cycles of S-1 adjuvant chemotherapy, and oral omega-3 fatty acid during  
14  
15  
16 chemotherapy (Figure1). This study includes a 3-year period of registration and 1 year of  
17  
18  
19 follow-up. This study protocol follows the SPIRIT-statement.  
20  
21  
22  
23  
24

### 25 **Sample size**

26  
27  
28 The sample size was calculated based on the primary endpoint. This study is planned for 55  
29  
30  
31 participants. Previous study reported that the completion percentage of four courses of S-1  
32  
33  
34 chemotherapy was 76% in biliary tract cancer patients<sup>3</sup>. The reasons for discontinuance were  
35  
36  
37 adverse events (12%) and early recurrence (12%). We set 0.76 as the threshold proportion.  
38  
39  
40 Aoyama *et al* reported that administration of nutritional support with omega-3 fatty acid  
41  
42  
43 caused a 100% completion rate of adjuvant chemotherapy in gastric cancer<sup>6</sup>. We set 0.9 as  
44  
45  
46 the estimated proportion for our study because biliary tract cancer has about 10% early  
47  
48  
49 recurrence.  
50

51  
52 Under the estimation of 0.76 for threshold proportion and 0.9 for estimated proportion,  
53  
54  
55 51 participants are required for one-sided significance level 0.025 and power 1-0.2. There is a  
56  
57  
58 potential for a few dropouts from follow-up, so we plan for a total of 55 participants.  
59  
60



1  
2  
3  
4 There are about 25 target surgical operations in our institution per year, so we set a  
5  
6  
7 registration period of 3 years.  
8  
9

### 10 11 12 13 **Study participants**

14  
15  
16 Potential participants are all patients on whom surgical resection of biliary tract cancer is  
17  
18 performed during the study period. After surgical resection, participants are recruited for the  
19  
20 study, and they must provide written, informed consent before enrolling in the study.  
21  
22

23  
24  
25 Participants who satisfy all the inclusion criteria and none of the exclusion criteria (Table1)  
26  
27 are enrolled in this study.  
28  
29

### 30 31 32 33 34 **Schedule of the study**

35  
36  
37 Table2 shows the schedule of the study. After written informed consent, researchers perform  
38  
39 a screening test and check inclusion and exclusion criteria. If participants meet all eligibility  
40  
41 criteria, they are registered in the study. No protocol treatment before registration and no  
42  
43 revocation after registration are permitted. After all data are entered and registration numbers  
44  
45 given, then patients are counted as registered. Participants undergo protocol treatment within  
46  
47  
48  
49  
50  
51  
52 14 days after registration.  
53

54  
55 After registration this study consists of a maximum two-week pre-observation period,  
56  
57  
58 24-week treatment period, and four-week post-observation period. During the pre-  
59  
60

1  
2  
3  
4 observation period, participants taking an antilipemic agent change their drug to omega-3  
5  
6  
7 fatty acid formulations.  
8  
9

10 Participants do not receive any anti-cancer treatment after protocol treatment until the  
11  
12  
13 recurrence of cancer.  
14  
15  
16  
17  
18

## 19 **Intervention**

### 20 *S-1*

21  
22  
23  
24  
25 Participants receive S-1 orally with the amount calculated considering body surface area and  
26  
27  
28 creatinine clearance (Table3). Body weight for this calculation is that at registration. They  
29  
30  
31 receive S-1 twice daily for 28 consecutive days, and the drug is withdrawn for the next 14  
32  
33  
34 days (one cycle). This administration of S-1 is repeated every six weeks for up to four cycles.  
35  
36  
37 If a cycle ends within 42 days for some reason, participants undergo an additional cycle until  
38  
39  
40 the end of the 24-week treatment period. A cycle is not newly started after a treatment period,  
41  
42  
43 and ongoing cycles on day 168 of the treatment period continue to the end.  
44  
45

46 Participants should meet the following criteria when starting the treatment from the  
47  
48  
49 second cycle: 1) ECOG performance status is 0, 1, or 2; 2) neutrophil count is at 1000  
50  
51  
52 cells/ $\mu$ L or higher; 3) platelet count is at 50000 cells / $\mu$ L or higher; 4) AST concentration is  
53  
54  
55 three times the upper limit or lower; 5) ALT concentration is three times the upper limit or  
56  
57  
58 lower; 6) T-Bil concentration is 1.5 times the upper limit or lower; 7) percutaneous arterial  
59  
60

1  
2  
3  
4 oxygen saturation is 90 % or more, and respiratory status dose is not worse than at  
5  
6  
7 registration; and 8) researchers consider the treatment can be performed safely.  
8  
9

### 10 *Omega-3 fatty acid formulations*

11  
12  
13 All participants take LOTRIGA 2g® (Takeda pharmaceutical Co. Ltd) which include 2g of  
14  
15  
16 omega-3 fatty acid from day one to day 168 of the treatment period.  
17  
18

### 19 *Withdrawal and reduction of the drug*

20  
21  
22 If any of adverse events are observed, researchers should withdraw S-1 and omega-3 fatty  
23  
24  
25 acid formulations. When participants meet the criteria for restart within seven days, they  
26  
27  
28 restart S-1 as the same cycle. In this case, the next cycle can start from the scheduled day  
29  
30  
31 with at least a seven-day interval. When participants do not meet the criteria for restart after  
32  
33  
34 more than 8 days, the cycle stops at that time. If participants meet the starting criteria, they  
35  
36  
37 can start a new cycle. When participants do not meet the restart criteria after more than 42  
38  
39  
40 days since the last day of taking S-1, they should stop the protocol treatment.  
41  
42

43  
44 When restarting S-1 after withdrawal due to an adverse event, participants get a  
45  
46 reduced dose of S-1. The daily dose of S-1 is reduced from 120 mg to 100mg, from 100 mg  
47  
48  
49 to 80 mg, from 80 mg to 60mg, or from 60mg to 50mg. Participants have two opportunities  
50  
51  
52 for reducing the drug. Participants taking 50mg of S-1 should stop the protocol treatment.  
53  
54

55  
56 If participants develop febrile neutropenia, they should be evaluated for t infectious  
57  
58 status, and antimicrobial agent or granulocyte colony stimulating factor (G-CSF) is used.  
59  
60

### *Adherence*

Researchers provide patient compliance instructions, and confirm at each visit the remnant of drugs and whether participants have ingested the correct dose of S-1.

### **Concomitant drugs and therapy**

There is no concomitant drugs and therapy during this study.

### **Outcomes**

#### *Primary outcome*

The primary outcome is the completion rate of adjuvant chemotherapy. Completion is defined as participants who can finish a total of four cycles of S-1 adjuvant chemotherapy, regardless of relative performance index (RP: proportion of actual dose per expected dose) after surgical resection of biliary tract cancer.

#### *Secondary outcome*

Secondary outcomes are as follows:

- 1) Post-operative cholangitis
- 2) Time to recurrence or distant metastasis
- 3) Changes of nutritional index from registration until the completion of chemotherapy
- 4) Changes of lymphocyte blast transformation test induced by phytohemagglutinin (PHA) and concanavalin A (Con-A) during adjuvant chemotherapy

1  
2  
3  
4 5) Change of diamine oxidase serum activity (DAO) during adjuvant chemotherapy  
5  
6

7 6) All adverse events after medication. A modified version of The Common Terminology  
8  
9

10 Criteria for Adverse Events (CTCAE v4.0) is used to grade adverse events.  
11  
12

13 Prospective adverse events are as follows: coagulation disorder, lipid metabolism disorder,  
14  
15 abnormality of laboratory data, fatigue, fever, gastrointestinal disorders, skin and  
16  
17 subcutaneous tissue disorders, metabolism and nutrition disorders, nervous system disorders,  
18  
19 blood and lymphatic system disorders, eye disorders, infections and infestations, injury and  
20  
21 procedural complications.  
22  
23  
24  
25  
26  
27  
28  
29  
30

### 31 **Data analysis** 32 33

34 Participants who are recruited into this study and receive administration of one of the test  
35  
36 drugs at least once are included in the full analysis set (FAS). Participants who cannot  
37  
38 provide baseline data and have serious violations of protocol are not included in the FAS. Per  
39  
40 protocol set (PPS) is defined as participants in the FAS who comply with exclusion criteria,  
41  
42 concomitant drugs, and concomitant therapy. The analysis of FAS is performed for each  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### 55 **Primary outcome** 56 57

58 The point estimate of the completion rate of S-1 and 95% confidence interval (CI) is  
59  
60

1  
2  
3  
4 calculated. Participants who complete S-1 are defined as participants who have performed  
5  
6  
7 four scheduled cycles of S-1, or have continued treatment for 168 days.  
8  
9

### 10 11 12 13 Secondary outcomes

14  
15  
16 Analyses of secondary outcomes take the form of simple descriptive statistics (e.g.,  
17  
18 proportions and IQRs, means and SDs) and where appropriate, point estimates of effect sizes  
19  
20 (e.g., mean differences) and associated 95% CIs. The recurrence-free survival curves  
21  
22  
23  
24  
25 iscalculated using the Kaplan-Meier method, and 95% CIs are calculated.  
26  
27  
28  
29  
30

### 31 Safety analysis

32  
33  
34 For the evaluation of the safety of the study, all adverse events due to the study are counted.  
35  
36  
37 Severe adverse events are defined as the following three events: Grade 4 of non-blood system  
38  
39  
40 disorder, early mortality within 30 days after the last treatment, or mortality causally related  
41  
42  
43 to the protocol treatment.  
44  
45

46 Interim analysis is be performed in this study. All statistical analyses are conducted  
47  
48  
49 using JMP software (version 13.0, SAS, Cray, NC, USA).  
50  
51  
52  
53  
54

### 55 **Data management**

56  
57  
58 Researchers make case report forms (CRF) for each participant. Modification of CRF is  
59  
60

1  
2  
3  
4 permitted only when it does not exceed the prescribed range and is not a burden to  
5  
6  
7 participants. The principal investigator confirms and signs the CRF. CRFs are made at  
8  
9  
10 registration (within two weeks), treatment period (each two cycles), end of treatment (within  
11  
12  
13 30 days), and in the follow-up period.  
14  
15  
16  
17  
18

### 19 **Data and safety monitoring**

20  
21  
22 Independent data and safety monitoring is conducted. The following materials are reviewed  
23  
24  
25 every six months: informed consent obtained and signed, participant retention, study  
26  
27  
28 implementation system, study safety and data, and study progress.  
29  
30  
31  
32  
33

### 34 **Confidentiality**

35  
36  
37 All study-related information are stored securely at the study site and identified by a coded  
38  
39  
40 number only to maintain participant confidentiality. All participant information are stored in  
41  
42  
43 locked file cabinets in areas with limited access. All records that contain names or other  
44  
45  
46 personal identifiers are stored separately from study records identified by code number. All  
47  
48  
49 local databases are secured with password-protected access systems. Participants' study  
50  
51  
52 information are not be released outside of the study without the written permission of the  
53  
54  
55 participant.  
56  
57  
58  
59  
60

## ETHICS AND DISSEMINATION

This study is conducted according to the declaration of Helsinki, Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan, and Management Guidelines of Conflict of Interest in our institution. The protocol has been approved by the Institutional Review Board of Kobe University Hospital (No 290086).

Researchers explain the study to potential participants with information sheets.

Patients are given the opportunity to ask questions and have enough time to consent to the study. Researchers obtain written consent from patients willing to participate in the study.

Information sheets and consent forms are provided for all participants involved in the study.

The result of this study will be disseminated through academic conferences and peer-reviewed journals. All authors will review and approve the paper before publication. If there are several papers related to this study, the investigator will appoint each author.

## DISCUSSION

The biliary tract is divided into four anatomical component ; they are intrahepatic bile duct, extrahepatic bile duct, gallbladder, and ampulla of vater. Cancer staging is different in each origin, and the prognosis is also different. To select proper patients for this study, we exclude patients of Stage I of perihilar cholangiocarcinoma and gallbladder cancer and Stage IA of cancer ampulla of vater and distal bile duct cancer. That is because these Stage IA or Stage I



1  
2  
3  
4 patients have a better prognosis compared to patients with other stages. The five-year survival  
5  
6  
7 rate of Stage I gallbladder cancer patients and Stage IA ampulla of vater cancer patients are  
8  
9  
10 87.5 % and 82.9 %, respectively. Although cancer of Stage I (five-year survival rate is  
11  
12  
13 69.8%) perihilar cholangiocarcinoma and Stage IA (59.5%) distal biliary tract cancer patients  
14  
15  
16 have worse prognosis than gallbladder cancer and cancer of ampulla of vater patients, cancer  
17  
18  
19 death is not common. Potential reasons for poor prognosis are perioperative death and late  
20  
21  
22 complications like cholangitis. These patients get few benefits from adjuvant chemotherapy.  
23  
24  
25 On the other hand, the five-year survival rate of Stage I intrahapetic cholangiocarcinoma  
26  
27  
28 patients is 36.3 % which is worse than the same stage of other biliary tract cancers. Adjuvant  
29  
30  
31 chemotherapy seems to be beneficial for patients of Stage I intrahepatic cholangiocarcinoma.  
32  
33  
34 Though the target for adjuvant chemotherapy for biliary tract cancer is still controversial, we  
35  
36  
37 have selected the relatively poor-prognosis group in biliary tract cancer. Moreover, to align  
38  
39  
40 the patients post-surgical background, we have selected the type of surgical operation which  
41  
42  
43 includes biliary reconstruction.  
44  
45

46 The most common reason for interruption of adjuvant chemotherapy was an adverse  
47  
48  
49 event in biliary tract cancer<sup>3</sup>. Seo et al<sup>14</sup> reported that hypoalbuminemia (<3.5mg/dL) was  
50  
51  
52 associated with adverse events greater than grade 3 in gastric cancer. Hypoalbuminemia is  
53  
54  
55 also one risk factor for interruption of adjuvant chemotherapy in pancreatic cancer patients<sup>15</sup>.  
56  
57  
58 The albumin level is one of the indications of nutritional status. According to a previous  
59  
60

1  
2  
3  
4 study, body weight loss is associated with the continuance of adjuvant chemotherapy <sup>6</sup>, and  
5  
6  
7 nutritional intervention including omega-3 fatty acid has an effect on several cancers <sup>7 8</sup>.  
8  
9

10 It is well known that chemotherapy including 5-fluorouracil(5-FU) causes  
11  
12 gastrointestinal injury<sup>16</sup>. 5-FU also showed toxicity to helper T cells in mice, which seems to  
13  
14 cause immunosuppression<sup>17</sup>. These changes might result in bacterial translocation(BT)<sup>18</sup>.  
15  
16 From the viewpoint of immunity and infection, omega-3 fatty acid plays a preventive role.  
17  
18 Matsunaga H et al. reported that a diet containing omega-3 fatty acid suppresses the  
19  
20 thickening of mucous, submucosa, and the muscular layer due to inflammation in mice  
21  
22 compared with the control diet<sup>19</sup>. Moreover omega-3 fatty acid inhibits infiltration of  
23  
24 inflammatory cells into the muscularis mucosa<sup>19</sup>. Moreover, the rate of bacterial translocation  
25  
26 and ileal change in pre- and postoperative feeding with omega-3 fatty acid in rats on which  
27  
28 were performed common bile duct ligation were the same as that of the control group, while  
29  
30 bacterial translocation and atrophy of intestinal mucosa in postoperative feeding group  
31  
32 increased compared to the control group<sup>20</sup>. From these reports, it is thought that the  
33  
34 administration of omega-3 fatty acid from the start of chemotherapy when intestinal  
35  
36 mucosal disorder is not yet occurring can keep intestinal mucosa normal and prevent  
37  
38 intestinal inflammation and the interruption of anticancer agent by infection.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

55 In addition to the nutritional aspect, omega-3 fatty acid has an anti-inflammatory effect.  
56  
57 Post biliary reconstruction, it is easy for patients to experience cholangitis and stop  
58  
59  
60

1  
2  
3  
4 chemotherapy. Omega-3 fatty acid is known to calm acute inflammation by regulation of  
5  
6  
7 inflammatory cytokines<sup>9</sup>. Furthermore, in vivo experiments showed suppression of the  
8  
9  
10 proliferation of cancer cells by inducing apoptosis in several cancers<sup>10 12 13</sup>.

11  
12  
13 In this study we expect that omega-3 fatty acid will improve the completion rate of  
14  
15  
16 adjuvant chemotherapy and will result in a good prognosis in biliary tract cancer patients.

17  
18  
19 **Acknowledgments** I would like to deeply thank for Dr. S Murakami and Kobe University  
20  
21  
22 Hospital Clinical & Translational Research Center who gave great supports in setting up this  
23  
24  
25 research and preparing manuscript.

26  
27  
28 **Registry** This study is registered at UMIN Clinical Trials Registry (UMIN000031247) and  
29  
30  
31 Japan Registry of Clinical Trials (jRCTs051180007):.

32  
33  
34 Registration Data Set: [https://upload.umin.ac.jp/cgi-open-](https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000035677)  
35  
36  
37 [bin/ctr/ctr\\_view.cgi?recptno=R000035677](https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000035677)

38  
39  
40 Registration Data Set: <https://jrct.niph.go.jp/detail/349>

41  
42  
43 **Contributors** All the authors contributed to the study design and writing and revising the  
44  
45  
46 protocol. All authors read and approved the final manuscript.

47  
48  
49 **Funding** This study has received no specific grant from any funding agency in the public,  
50  
51  
52 commercial or not-for-profit sectors.

53  
54  
55 **Competing interests** None declared.

56  
57  
58 **Patient consent** Obtained

1  
2  
3  
4 **Patient and Public Involvement** We did not involve patients or the public in our work  
5  
6

7 **Ethics approval** Kobe University Clinical Research Ethical Committee  
8  
9

10 **Issue date:** September 20, 2018  
11  
12

13 **Protocol amendment number:** 1.4  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 1 Inclusion and exclusion criteria

<b>Inclusion criteria</b>
<p>1) pathologically diagnosed as adenocarcinoma (in case of combined cancer, adenocarcinoma is dominant)</p> <p>2) UICC stage is as follows:</p> <ul style="list-style-type: none"> <li>- any T, N0 or N1 and M0 in intrahepatic cholangiocarcinoma</li> <li>- T2, 3, 4, N0, and M0 in extrahepatic cholangiocarcinoma</li> <li>- any T, N1 and M0 in extrahepatic cholangiocarcinoma</li> </ul> <p>3) age 20 - 80 years or younger</p> <p>4) ECOG performance status is 0 or 1</p> <p>5) CT and MRI show no metastases and moderate or less pleural effusion* or ascites**</p> <p>6) Performed pancreaticoduodenectomy, hepatectomy, bile duct resection, caudal lobectomy and/or cholecystectomy, with D1 or more extensive lymphadenectomy***</p> <p>7) No history of any prior chemotherapy or radiation therapy</p> <p>8) 14 to 70 days from surgical resection</p> <p>9) Good oral intake</p> <p>10) No watery diarrhea</p> <p>meets all the following laboratory data values within 14 days before registration</p> <ul style="list-style-type: none"> <li>a) neutrophil <math>\geq 1,200/\text{mm}^3</math></li> <li>b) platelet <math>\geq 10,000/\text{mm}^3</math></li> <li>c) hemoglobin <math>\geq 8.0\text{g/L}</math></li> <li>d) total bilirubin <math>\leq 2.0\text{ mg/dL}</math></li> <li>e) AST <math>\leq 100\text{IU/L}</math></li> <li>f) ALT <math>\leq 100\text{IU/L}</math></li> <li>g) serum creatinine <math>\leq 1.2\text{mg/dL}</math></li> <li>h) creatinine clearance (CC) <math>\geq 40\text{ mL/min}</math> (CC calculated by Cockcroft-Gault Equation)</li> </ul> <p>11) Written informed consent</p>
<b>Exclusion criteria</b>
<p>1) Allergic predisposition or drug hypersensitivity</p> <p>2) Double or multiple cancer diagnosed or treated in the past five years. (except for carcinoma in situ)</p> <p>3) Active infectious disease (except for virus hepatitis)</p> <p>4) Fver above 38 degrees C</p> <p>5) Current pregnancy, breastfeeding, planning to become pregnant during the study</p> <p>6) Psychological disease and/or symptoms</p>

- 7) Severe liver or renal dysfunction
- 8) Uncontrollable hypertension or diabetes mellitus
- 9) Uncontrollable ischemic heart disease:
  - angina developed or worsening within three weeks
  - myocardial infarction developed within six months
- 10) Taking flucytosine, phenytoin, or warfarin potassium
- 11) Interstitial pneumonitis, pulmonary fibrosis, and pulmonary emphysema
- 12) Taking omega-3 fatty acid formulations
- 13) Considered unsuitable by their attending physician

CT computed tomography MRI magnetic resonance imaging

\*Moderate plural effusion is defined as effusion occupying one third of the lung field by chest X-ray. \*\* Moderate ascites is defined as ascites within the pelvic cavity. \*\*\*In case of intrahepatic cholangiocarcinoma without invasion to hepatic portal region, lymphadenectomy is not necessary.



1  
2  
3  
4 operation time). Screening tests are general status, blood test, urinary test, computed  
5  
6  
7 tomography and electrocardiogram. General status includes blood pressure, body temperature,  
8  
9  
10 pulse rate and respiratory rate. Blood test includes complete blood count, differential count of  
11  
12  
13 leukocytes, total protein, albumin, total bilirubin, creatinine, aspartate transaminase, alanine  
14  
15  
16 aminotransferase, alkaline phosphatase, lactate dehydrogenase, Na, K, total cholesterol, HDL  
17  
18  
19 cholesterol, LDL cholesterol, and triglyceride.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Table 3 dose of S-1

	dose of S-1	
body surface area (m <sup>2</sup> )	50mL/min ≤ Ccr < 60mL/min	60mL/min ≤ Ccr
under 1.25	60mg/day	80mg/day
1.25 to 1.5	80mg/day	100mg/day
over 1.5	100mg/day	120mg/day

## Figure legend

Figure1 Summary of study.

## References

1. Miyakawa S, Ishihara S, Horiguchi A, et al. Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. *J Hepatobiliary Pancreat Surg* 2009;16(1):1-7. doi: 10.1007/s00534-008-0015-0 [published Online First: 2008/12/27]
2. Waseem D, Tushar P. Intrahepatic, perihilar and distal cholangiocarcinoma: Management and outcomes. *Ann Hepatol* 2017;16(1):133-39. doi: 10.5604/16652681.1226927 [published Online First: 2017/01/05]
3. Nakachi K, Konishi M, Ikeda M, et al. Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer. *Int J Clin Oncol* 2018 doi: 10.1007/s10147-018-1283-6 [published Online First: 2018/05/01]
4. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer

- 1  
2  
3  
4 with S-1, an oral fluoropyrimidine. *N Engl J Med* 2007;357(18):1810-20. doi:  
5  
6  
7 10.1056/NEJMoa072252 [published Online First: 2007/11/06]  
8  
9
- 10 5. Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine  
11  
12 for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial  
13  
14 (JASPAC 01). *Lancet* 2016;388(10041):248-57. doi: 10.1016/S0140-  
15  
16 6736(16)30583-9 [published Online First: 2016/06/07]  
17  
18
- 19 6. Aoyama T, Yoshikawa T, Shirai J, et al. Body weight loss after surgery is an independent  
20  
21 risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. *Ann Surg*  
22  
23 *Oncol* 2013;20(6):2000-6. doi: 10.1245/s10434-012-2776-6 [published Online First:  
24  
25 2012/12/18]  
26  
27
- 28 7. Aoyama T, Hayashi T, Fujikawa H, et al. [Effect of enteral nutrition enriched with  
29  
30 eicosapentaenoic acid on body weight loss and compliance with S-1 adjuvant  
31  
32 chemotherapy after gastric cancer surgery]. *Gan To Kagaku Ryoho*  
33  
34 2013;40(12):2289-91. [published Online First: 2014/01/08]  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45
- 46 8. Murphy RA, Mourtzakis M, Chu QS, et al. Nutritional intervention with fish oil provides a  
47  
48 benefit over standard of care for weight and skeletal muscle mass in patients with  
49  
50 nonsmall cell lung cancer receiving chemotherapy. *Cancer* 2011;117(8):1775-82. doi:  
51  
52 10.1002/cncr.25709 [published Online First: 2011/03/02]  
53  
54  
55  
56  
57
- 58 9. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. *Nature*  
59  
60

- 1  
2  
3  
4 2014;510(7503):92-101. doi: 10.1038/nature13479 [published Online First:  
5  
6  
7 2014/06/06]
- 10 10. Cao W, Ma Z, Rasenick MM, et al. N-3 poly-unsaturated fatty acids shift estrogen signaling  
11  
12 to inhibit human breast cancer cell growth. *PLoS One* 2012;7(12):e52838. doi:  
13  
14 10.1371/journal.pone.0052838 [published Online First: 2013/01/04]  
15  
16
- 19 11. Chagas TR, Borges DS, de Oliveira PF, et al. Oral fish oil positively influences nutritional-  
20  
21 inflammatory risk in patients with haematological malignancies during chemotherapy  
22  
23 with an impact on long-term survival: a randomised clinical trial. *J Hum Nutr Diet*  
24  
25 2017;30(6):681-92. doi: 10.1111/jhn.12471 [published Online First: 2017/04/05]  
26  
27  
28  
29
- 31 12. Mizoguchi K, Ishiguro H, Kimura M, et al. Induction of apoptosis by eicosapentaenoic acid  
32  
33 in esophageal squamous cell carcinoma. *Anticancer Res* 2014;34(12):7145-9.  
34  
35 [published Online First: 2014/12/17]  
36  
37  
38  
39
- 40 13. Shirota T, Haji S, Yamasaki M, et al. Apoptosis in human pancreatic cancer cells induced  
41  
42 by eicosapentaenoic acid. *Nutrition* 2005;21(10):1010-7. doi:  
43  
44 10.1016/j.nut.2004.12.013 [published Online First: 2005/09/15]  
45  
46  
47  
48
- 49 14. Seo SH, Kim SE, Kang YK, et al. Association of nutritional status-related indices and  
50  
51 chemotherapy-induced adverse events in gastric cancer patients. *BMC Cancer*  
52  
53 2016;16(1):900. doi: 10.1186/s12885-016-2934-5 [published Online First:  
54  
55 2016/11/20]  
56  
57  
58  
59  
60

- 1  
2  
3  
4 15. Matsumoto I, Tanaka M, Shirakawa S, et al. Postoperative Serum Albumin Level is a  
5  
6  
7 Marker of Incomplete Adjuvant Chemotherapy in Patients with Pancreatic Ductal  
8  
9  
10 Adenocarcinoma. *Ann Surg Oncol* 2015;22(7):2408-15. doi: 10.1245/s10434-014-  
11  
12 4280-7 [published Online First: 2014/12/10]
- 13  
14  
15  
16 16. Murakami M, Sato N, Tashiro K, et al. Effects of caloric intake on intestinal mucosal  
17  
18 morphology and immune cells in rats treated with 5-Fluorouracil. *J Clin Biochem Nutr*  
19  
20 2009;45(1):74-81. doi: 10.3164/jcbn.08-264 [published Online First: 2009/07/11]  
21  
22  
23  
24  
25 17. Merluzzi VJ, Last-Barney K, Susskind BM, et al. Recovery of humoral and cellular immunity  
26  
27 by soluble mediators after 5-fluorouracil-induced immunosuppression. *Clin Exp*  
28  
29 *Immunol* 1982;50(2):318-26. [published Online First: 1982/11/01]  
30  
31  
32  
33  
34 18. Tsuji E, Hiki N, Nomura S, et al. Simultaneous onset of acute inflammatory response,  
35  
36 sepsis-like symptoms and intestinal mucosal injury after cancer chemotherapy. *Int J*  
37  
38 *Cancer* 2003;107(2):303-8. doi: 10.1002/ijc.11196 [published Online First:  
39  
40 2003/09/02]  
41  
42  
43  
44  
45  
46 19. Matsunaga H, Hokari R, Kurihara C, et al. Omega-3 polyunsaturated fatty acids ameliorate  
47  
48 the severity of ileitis in the senescence accelerated mice (SAM)P1/Yit mice model. *Clin*  
49  
50 *Exp Immunol* 2009;158(3):325-33. doi: 10.1111/j.1365-2249.2009.04020.x  
51  
52  
53  
54  
55 [published Online First: 2009/10/02]  
56  
57  
58 20. Zulfikaroglu B, Zulfikaroglu E, Ozmen MM, et al. The effect of immunonutrition on  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

bacterial translocation, and intestinal villus atrophy in experimental obstructive  
jaundice. *Clin Nutr* 2003;22(3):277-81. [published Online First: 2003/05/27]

For peer review only




Figure 1. Summary of study

Figure legend  
Figure1 Summary of study.

89x89mm (96 x 96 DPI)

# Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	<a href="#">#1</a>	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	<a href="#">#2a</a>	Trial identifier and registry name. If not yet registered, name of intended registry	18
Trial registration: data set	<a href="#">#2b</a>	All items from the World Health Organization Trial Registration Data Set	18
Protocol version	<a href="#">#3</a>	Date and version identifier	18
Funding	<a href="#">#4</a>	Sources and types of financial, material, and other support	18
Roles and responsibilities: contributorship	<a href="#">#5a</a>	Names, affiliations, and roles of protocol contributors	18
Roles and responsibilities:	<a href="#">#5b</a>	Name and contact information for the trial sponsor	N/A

1	sponsor contact			
2	information			
3				
4	Roles and	<a href="#">#5c</a>	Role of study sponsor and funders, if any, in study design;	N/A
5	responsibilities:		collection, management, analysis, and interpretation of data;	
6	sponsor and funder		writing of the report; and the decision to submit the report for	
7			publication, including whether they will have ultimate authority	
8			over any of these activities	
9				
10				
11				
12	Roles and	<a href="#">#5d</a>	Composition, roles, and responsibilities of the coordinating	13-14
13	responsibilities:		centre, steering committee, endpoint adjudication committee,	
14	committees		data management team, and other individuals or groups	
15			overseeing the trial, if applicable (see Item 21a for data	
16			monitoring committee)	
17				
18				
19				
20	Background and	<a href="#">#6a</a>	Description of research question and justification for undertaking	5
21	rationale		the trial, including summary of relevant studies (published and	
22			unpublished) examining benefits and harms for each intervention	
23				
24				
25				
26	Background and	<a href="#">#6b</a>	Explanation for choice of comparators	7
27	rationale: choice of			
28	comparators			
29				
30				
31	Objectives	<a href="#">#7</a>	Specific objectives or hypotheses	5-6
32				
33				
34	Trial design	<a href="#">#8</a>	Description of trial design including type of trial (eg, parallel	6-7
35			group, crossover, factorial, single group), allocation ratio, and	
36			framework (eg, superiority, equivalence, non-inferiority,	
37			exploratory)	
38				
39				
40	Study setting	<a href="#">#9</a>	Description of study settings (eg, community clinic, academic	8-9
41			hospital) and list of countries where data will be collected.	
42			Reference to where list of study sites can be obtained	
43				
44				
45				
46	Eligibility criteria	<a href="#">#10</a>	Inclusion and exclusion criteria for participants. If applicable,	8
47			eligibility criteria for study centres and individuals who will	
48			perform the interventions (eg, surgeons, psychotherapists)	
49				
50				
51	Interventions:	<a href="#">#11a</a>	Interventions for each group with sufficient detail to allow	9-10
52	description		replication, including how and when they will be administered	
53				
54				
55	Interventions:	<a href="#">#11b</a>	Criteria for discontinuing or modifying allocated interventions	9-10
56	modifications		for a given trial participant (eg, drug dose change in response to	
57			harms, participant request, or improving / worsening disease)	
58				
59				
60				



1	Interventions:	<a href="#">#11c</a>	Strategies to improve adherence to intervention protocols, and	11
2	adherence		any procedures for monitoring adherence (eg, drug tablet return;	
3			laboratory tests)	
4				
5				
6	Interventions:	<a href="#">#11d</a>	Relevant concomitant care and interventions that are permitted or	11
7	concomitant care		prohibited during the trial	
8				
9				
10	Outcomes	<a href="#">#12</a>	Primary, secondary, and other outcomes, including the specific	11-12
11			measurement variable (eg, systolic blood pressure), analysis	
12			metric (eg, change from baseline, final value, time to event),	
13			method of aggregation (eg, median, proportion), and time point	
14			for each outcome. Explanation of the clinical relevance of chosen	
15			efficacy and harm outcomes is strongly recommended	
16				
17				
18				
19				
20	Participant timeline	<a href="#">#13</a>	Time schedule of enrolment, interventions (including any run-ins	8
21			and washouts), assessments, and visits for participants. A	
22			schematic diagram is highly recommended (see Figure)	
23				
24				
25	Sample size	<a href="#">#14</a>	Estimated number of participants needed to achieve study	7
26			objectives and how it was determined, including clinical and	
27			statistical assumptions supporting any sample size calculations	
28				
29				
30	Recruitment	<a href="#">#15</a>	Strategies for achieving adequate participant enrolment to reach	8
31			target sample size	
32				
33				
34	Allocation: sequence	<a href="#">#16a</a>	Method of generating the allocation sequence (eg, computer-	NA
35	generation		generated random numbers), and list of any factors for	
36			stratification. To reduce predictability of a random sequence,	this study
37			details of any planned restriction (eg, blocking) should be	is single-
38			provided in a separate document that is unavailable to those who	arm
39			enrol participants or assign interventions	
40				
41				
42				
43				
44	Allocation	<a href="#">#16b</a>	Mechanism of implementing the allocation sequence (eg, central	NA
45	concealment		telephone; sequentially numbered, opaque, sealed envelopes),	
46	mechanism		describing any steps to conceal the sequence until interventions	this study
47			are assigned	is single-
48				arm
49				
50				
51	Allocation:	<a href="#">#16c</a>	Who will generate the allocation sequence, who will enrol	NA
52	implementation		participants, and who will assign participants to interventions	
53				this study
54				is single-
55				arm
56				
57				
58				
59				
60				

1	Blinding (masking)	<a href="#">#17a</a>	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	NA this study is single- arm
2				
3				
4				
5				
6				
7				
8	Blinding (masking):	<a href="#">#17b</a>	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	NA this study is single- arm
9	emergency			
10	unblinding			
11				
12				
13				
14				
15				
16	Data collection plan	<a href="#">#18a</a>	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	13
17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27	Data collection plan:	<a href="#">#18b</a>	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	13
28	retention			
29				
30				
31				
32				
33	Data management	<a href="#">#19</a>	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	13-14
34				
35				
36				
37				
38				
39	Statistics: outcomes	<a href="#">#20a</a>	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	12-13
40				
41				
42				
43				
44				
45	Statistics: additional	<a href="#">#20b</a>	Methods for any additional analyses (eg, subgroup and adjusted analyses)	12-13
46	analyses			
47				
48				
49	Statistics: analysis	<a href="#">#20c</a>	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	13
50	population and			
51	missing data			
52				
53				
54	Data monitoring:	<a href="#">#21a</a>	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found,	14
55	formal committee			
56				
57				
58				
59				

if not in the protocol. Alternatively, an explanation of why a DMC is not needed

1			
2			
3			
4	Data monitoring:	<a href="#">#21b</a>	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial
5	interim analysis		
6			
7			
8			
9			
10			
11	Harms	<a href="#">#22</a>	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct
12			
13			
14			
15			
16	Auditing	<a href="#">#23</a>	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor
17			
18			
19			
20			
21	Research ethics approval	<a href="#">#24</a>	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval
22			
23			
24			
25	Protocol amendments	<a href="#">#25</a>	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)
26			
27			
28			
29			
30			
31			
32	Consent or assent	<a href="#">#26a</a>	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)
33			
34			
35			
36	Consent or assent: ancillary studies	<a href="#">#26b</a>	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable
37			
38			
39			
40			
41	Confidentiality	<a href="#">#27</a>	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial
42			
43			
44			
45			
46	Declaration of interests	<a href="#">#28</a>	Financial and other competing interests for principal investigators for the overall trial and each study site
47			
48			
49			
50	Data access	<a href="#">#29</a>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators
51			
52			
53			
54			
55			
56	Ancillary and post trial care	<a href="#">#30</a>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation
57			
58			
59			
60			

1	Dissemination	<a href="#">#31a</a>	Plans for investigators and sponsor to communicate trial results	15
2	policy: trial results		to participants, healthcare professionals, the public, and other	
3			relevant groups (eg, via publication, reporting in results	
4			databases, or other data sharing arrangements), including any	
5			publication restrictions	
6				
7				
8				
9	Dissemination	<a href="#">#31b</a>	Authorship eligibility guidelines and any intended use of	15
10	policy: authorship		professional writers	
11				
12				
13	Dissemination	<a href="#">#31c</a>	Plans, if any, for granting public access to the full protocol,	N/A
14	policy: reproducible		participant-level dataset, and statistical code	
15	research			
16				
17				
18	Informed consent	<a href="#">#32</a>	Model consent form and other related documentation given to	N/A
19	materials		participants and authorised surrogates	
20				
21				only in
22				japanese
23				
24	Biological specimens	<a href="#">#33</a>	Plans for collection, laboratory evaluation, and storage of	N/A
25			biological specimens for genetic or molecular analysis in the	
26			current trial and for future use in ancillary studies, if applicable	
27				
28				
29				

30 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND  
 31 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR](#)  
 32 [Network](#) in collaboration with [Penelope.ai](#)  
 33  
 34  
 35  
 36  
 37  
 38  
 39  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60

# BMJ Open

## Effectiveness of omega-3 fatty acid administration on completion rate of adjuvant chemotherapy for biliary tract cancer: study protocol for a single-center, open-label, single-arm, historically controlled study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029915.R1
Article Type:	Protocol
Date Submitted by the Author:	09-Jul-2019
Complete List of Authors:	Ueno, Kimihiko; Kobe University, Hepato-Biliary-Pancreatic Surgery Ajiki, Tetsuo; Kobe University Graduate School of Medicine, Hepato-Biliary-Pancreatic Surgery Tsugawa, Daisuke; Kobe University, Hepato-Biliary-Pancreatic Surgery Akita, Masayuki; Kobe University, Hepato-Biliary-Pancreatic Surgery Hashimoto, Yu; Kobe university, Hepato-Biliary-Pancreatic Surgery Awazu, Masahide; Kobe University, Hepato-Biliary-Surgery Mukubo, Hideyo; Kobe University, Hepato-Biliary-Pancreatic Surgery Komatsu, Shohei; Kobe University, Hepato-Biliary-Surgery Kuramitsu, Kaori; Kobe University, Hepato-Biliary-Surgery Terai, Sachio; Kobe University Graduate School of Medicine, Surgery Tanaka, Motofumi; Kobe University, Hepato-Biliary-Pancreatic Surgery Toyama, Hirochika; Kobe University, Hepato-Biliary-Pancreatic Surgery Kido, Masahiro; Kobe University, Hepato-Biliary-Surgery Fukumoto, Takumi; Kobe University, Hepato-Biliary-Pancreatic Surgery
<b>Primary Subject Heading</b>:	Surgery
Secondary Subject Heading:	Gastroenterology and hepatology
Keywords:	Biliary Tract Cancer, CHEMOTHERAPY, Adjuvant, Omega-3 fatty acid, S-1

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7 **Effectiveness of omega-3 fatty acid administration on completion rate of adjuvant**  
8  
9  
10 **chemotherapy for biliary tract cancer: study protocol for a single-center, open-label,**  
11  
12  
13 **single-arm, historically controlled study**  
14  
15  
16  
17  
18

19 Kimihiko Ueno Tetsuo Ajiki Daisuke Tsugawa Masayuki Akita Yu Hashimoto

20  
21  
22 Masahide Awazu Hideyo Mukubo Shohei Komatsu Kaori Kuramitsu Sachio Terai

23  
24  
25 Motofumi Tanaka Hirichika Toyama Masahiro Kido Takumi Fukumoto

26  
27  
28  
29  
30 Department of Hepato-Biliary-Pancreatic surgery Kobe University Graduate School of  
31  
32 Medicine; Kobe-city Hyogo Japan  
33  
34  
35  
36

37 **Corresponding Author**

38  
39 Kimihiko Ueno

40  
41  
42 7-5-2 Kusunoki-cho Cyuo-ku Kobe-city Hyogo-pref Japan

43  
44  
45 E-mail : [kueno.rhmn@gmail.com](mailto:kueno.rhmn@gmail.com)

46  
47  
48 TEL : 078-382-6302 FAX : 078-382-6307

49  
50  
51  
52 **Key Words:** Biliary Tract Cancer, Chemotherapy, Adjuvant, Omega-3 fatty acid, S-1

53  
54  
55  
56  
57 **Word count:** 3,366 words

## ABSTRACT

**Introduction:** Multimodal treatment prolongs the survival of patients with biliary tract cancer (BTC). However, the chemotherapy choices for this disease are few, and completing each chemotherapy session is important. Adjuvant chemotherapy has been attempted for BTC, but has only had a 75% completion rate. Body weight loss and cholangitis are reasons for the interruption of chemotherapy. Previous reports suggested that nutritional intervention with omega-3 fatty acids maintained body weight and improved the completion rate for chemotherapy. Moreover, omega-3 fatty acids have an anti-inflammatory effect. Therefore, we theorized that omega-3 fatty acids would improve the completion rate of adjuvant chemotherapy in patients with BTC. The aim of this study is thus to evaluate the effectiveness of omega-3 fatty acids for patients planning adjuvant chemotherapy for BTC.

**Method and analysis:** This study is a single center, open-label, single-arm, historically controlled study with a planned enrollment of 55 participants. Protocol treatment consists of four courses of S-1 adjuvant chemotherapy and an oral omega-3 fatty acid pharmaceutical adjuvant (LOTRIGA 2g® [Takeda pharmaceutical Co. Ltd]), which includes 2 g of omega-3 fatty acids from day one until day 168 of the treatment period. The primary endpoint is the

1  
2  
3  
4 completion rate of four total courses of S-1. Secondary endpoints are post-operative  
5  
6  
7 cholangitis, time to recurrence or distant metastasis, changes in nutritional index, changes in  
8  
9  
10 the lymphocyte blast transformation test induced by phytohemagglutinin, and concanavalin A  
11  
12  
13 and diamine oxidase serum activity during adjuvant chemotherapy. All adverse events will be  
14  
15  
16 evaluated.

17  
18  
19 **Ethics and dissemination:** This protocol was approved by the Institutional Review Board of  
20  
21  
22 Kobe University Hospital. The findings from this study will be presented at national and  
23  
24  
25 international conferences and published in peer-reviewed journals.

26  
27  
28 **Trial registration number:** UMIN Clinical Trials Registry UMIN000031247.  
29  
30  
31

## 32 33 34 **ARTICLE SUMMARY**

### 35 36 37 **Strengths and limitations of this study**

38  
39  
40 # This study investigates the effectiveness of omega-3 fatty acids on the completion rate of  
41  
42  
43 adjuvant chemotherapy for BTC.  
44

45  
46 # This study is well planned for the selection of participants with BTC based on four  
47  
48  
49 different cancers depending on location.  
50

51  
52 # A major limitation of this study is related to it being a historically controlled study, which  
53  
54  
55 includes some bias.  
56

57  
58 # Because the primary endpoint of this study is the completion rate of chemotherapy, not the  
59  
60



1  
2  
3  
4 prognosis of patients, the effect on survival can only be interpreted as a guide.  
5  
6  
7  
8  
9

## 10 **INTRODUCTION**

11  
12  
13 While surgical resection is a definitive treatment for biliary tract cancer (BTC), the 5-year  
14  
15 survival rate is about 30–50%<sup>1</sup>, which is lower than that of other gastrointestinal cancers.  
16  
17

18  
19 Because of the limitation of surgical resection, multimodal treatment is expected to improve  
20  
21 rates of survival<sup>2</sup>. In spite of the importance of adjuvant chemotherapy, the initiation and  
22  
23 continuation of this in patients have proven difficult after biliary surgery. Biliary surgery,  
24  
25 such as liver resection and pancreaticoduodenectomy, is very invasive, and easily results in  
26  
27 delayed recovery as well as bacterial translocation (BT) that arises from malnutrition and  
28  
29 immunological deterioration. Uncontrolled bacterial translocation causes cholangitis that  
30  
31 interrupts chemotherapy. A feasibility study of S-1 adjuvant chemotherapy for BTC showed  
32  
33 that 75.8% of patients completed a 24-week protocol<sup>3</sup>. The main causes of discontinuation  
34  
35 were adverse events and relapse. This rate is similar to that for gastric (78%)<sup>4</sup> and pancreatic  
36  
37 (72%) cancers<sup>5</sup>. Few chemotherapy choices for BTC exist and, therefore, the completion of  
38  
39 each chemotherapy session is essential. It therefore follows that an improvement in the  
40  
41 completion rate for adjuvant chemotherapy is important for the treatment of BTC.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

54  
55 Previous reports have suggested that body weight loss may be a reason for  
56  
57 interruptions in adjuvant chemotherapy<sup>6</sup>. Nutritional intervention with omega-3 fatty acids  
58  
59  
60

1  
2  
3  
4 maintained body weight <sup>7 8</sup> and improved the completion rate of adjuvant chemotherapy <sup>7</sup>.

5  
6  
7 Omega-3 fatty acids are metabolized to lipid mediators that evoke an anti-inflammatory  
8  
9  
10 response as well as novel pro-resolving mechanisms, and enhances microbial clearance <sup>9</sup>. In  
11  
12  
13 addition, enteral immunonutrition using omega-3 fatty acids reduces bacterial translocation  
14  
15  
16 and atrophy of intestinal mucosal villi in rats with obstructive jaundice. Omega-3 fatty acids  
17  
18  
19 are expected to be a nutritional intervention for patients after biliary surgery in terms of the  
20  
21  
22 maintenance of body weight and immunity. Moreover, since previous reports have suggested  
23  
24  
25 an anti-tumor effect for omega-3 fatty acids <sup>10-13</sup>, this is an appropriate drug for cancer  
26  
27  
28 patients.  
29  
30

31 The aim of this study is to evaluate the efficacy of omega-3 fatty acids on adjuvant  
32  
33  
34 chemotherapy. Because patients to whom chemotherapy was administered tended to reduce  
35  
36  
37 their dietary intake, and those after biliary surgery are prone to cholangitis, omega-3 fatty  
38  
39  
40 acids are used in this study for nutritional support and as anti-inflammatory treatment. We  
41  
42  
43 will conduct this study with the hypothesis that omega-3 fatty acids improve tolerance for  
44  
45  
46 adjuvant chemotherapy after biliary surgery with regard to increasing body weight and  
47  
48  
49 reducing cholangitis.  
50  
51  
52  
53  
54

## 55 **METHODS AND ANALYSIS**

### 56 57 58 **Study design** 59 60

1  
2  
3  
4 This study is a single-center, open-label, single-arm, historically controlled study of patients  
5  
6  
7 who are administered S-1 after surgical resection of BTC. The aim of this study is to examine  
8  
9  
10 any improvement in completion rates of adjuvant chemotherapy by the administration of  
11  
12  
13 omega-3 fatty acids. All participants are scheduled to receive administration of four cycles of  
14  
15  
16 S-1 adjuvant chemotherapy, and oral omega-3 fatty acids during chemotherapy (Figure 1).

17  
18  
19 This study includes a 3-year period of registration and one year of follow-up. This study  
20  
21  
22 protocol follows the Standard Protocol Items: Recommendations for Interventional Trials  
23  
24  
25 (SPIRIT) statement.  
26  
27  
28  
29  
30

### 31 **Sample size**

32  
33  
34 The sample size was calculated based on the primary endpoint. This study is planned for 55  
35  
36  
37 participants. A previous study reported that the percentage completion for four courses of S-1  
38  
39  
40 chemotherapy was 76% in patients with BTC<sup>3</sup>. The reasons for discontinuance were adverse  
41  
42  
43 events (12%) and early recurrence (12%). We set 0.76 as the threshold proportion. Aoyama et  
44  
45  
46 al. reported that administration of nutritional support with omega-3 fatty acids caused a 100%  
47  
48  
49 completion rate for adjuvant chemotherapy in gastric cancer<sup>6</sup>. We set 0.9 as the estimated  
50  
51  
52 proportion for our study because BTC has about a 10% early recurrence rate.  
53  
54

55 Under an estimation of 0.76 for a threshold proportion and 0.9 for an estimated  
56  
57  
58 proportion, 51 participants are required for a one-sided significance level 0.025 and a power  
59  
60

1  
2  
3  
4 of 1–0.2. There is a potential for a few dropouts from follow-up, so we plan for a total of 55  
5  
6  
7 participants. If the early recurrence rate is the same as that of a previous report (12%) and the  
8  
9  
10 estimated proportion is 0.88, the power will be 0.56.  
11  
12

13         There are about 25 target surgical operations in our institution per year, so we set a  
14  
15  
16 registration period of 3 years.  
17  
18  
19  
20  
21

### 22 **Study participants**

23  
24  
25 Potential participants are all patients in whom the surgical resection of BTC is performed  
26  
27  
28 during the study period. After surgical resection, participants are recruited and must provide  
29  
30  
31 written, informed consent before enrollment for the study. Participants who satisfy all the  
32  
33  
34 inclusion criteria and none of the exclusion criteria (Table 1) are enrolled in this study.  
35  
36  
37  
38  
39

### 40 **Schedule of the study**

41  
42  
43 Table 2 shows the schedule of the study. After written, informed consent, researchers perform  
44  
45  
46 a screening test and check inclusion and exclusion criteria. If participants meet all eligibility  
47  
48  
49 criteria, they are registered in the study. No protocol treatment before registration and no  
50  
51  
52 revocation after registration are permitted. After all data are entered and registration numbers  
53  
54  
55 given, then patients are counted as registered. Participants undergo protocol treatment within  
56  
57  
58 14 days after registration.  
59  
60

1  
2  
3  
4 After registration, this study consists of a maximum two-week pre-observation period,  
5  
6  
7 24-week treatment period, and four-week post-observation period. During the pre-  
8  
9  
10 observation period, participants taking an antilipemic agent change their drug to omega-3  
11  
12  
13 fatty acid formulations.  
14

15  
16 Participants do not receive any anti-cancer treatment after protocol treatment until the  
17  
18  
19 recurrence of cancer.  
20  
21  
22  
23  
24

## 25 **Intervention**

### 26 *S-1*

27  
28  
29  
30  
31 Participants receive S-1 orally with the amount calculated considering body surface area and  
32  
33  
34 creatinine clearance (Table 3). Body weight for this calculation is that at registration. They  
35  
36  
37 receive S-1 twice daily for 28 consecutive days, and the drug is withdrawn for the next 14  
38  
39  
40 days (one cycle). This administration of S-1 is repeated every six weeks for up to four cycles.  
41  
42  
43 If a cycle ends within 42 days for some reason, participants undergo an additional cycle until  
44  
45  
46 the end of the 24-week treatment period. A cycle is not newly started after a treatment period,  
47  
48  
49 and ongoing cycles on day 168 of the treatment period continue to the end.  
50  
51

52  
53 Participants should meet the following criteria when starting the treatment from the  
54  
55  
56 second cycle: 1) Eastern Cooperative Oncology Group (ECOG) performance status is 0, 1, or  
57  
58  
59 2; 2) neutrophil count is 1,000 cells/ $\mu$ L or higher; 3) platelet count is 5,0000 cells/ $\mu$ L or  
60

1  
2  
3  
4 higher; 4) aspartate aminotransferase (AST) concentration is less than three times the upper  
5  
6  
7 limit; 5) alanine aminotransferase (ALT) concentration is less than three times the upper  
8  
9  
10 limit; 6) total bilirubin (T-Bil) concentration is less than 1.5 times the upper limit; 7)  
11  
12  
13 percutaneous arterial oxygen saturation is 90% or more, and respiratory status dose is not  
14  
15  
16 worse than at registration; and 8) researchers consider the treatment can be performed safely.  
17  
18

### 19 *Omega-3 fatty acid formulations*

20  
21  
22 All participants take LOTRIGA 2g<sup>®</sup> (Takeda pharmaceutical Co. Ltd), which includes 2 g  
23  
24  
25 of omega-3 fatty acids from day one to day 168 of the treatment period.  
26  
27

### 28 *Withdrawal and reduction of the drug*

29  
30  
31 If any adverse events are observed, researchers should withdraw S-1 and omega-3 fatty acid  
32  
33  
34 formulations. When participants meet the criteria for restarting within seven days, they restart  
35  
36  
37 S-1 as the same cycle. In this case, the next cycle can start from the scheduled day with at  
38  
39  
40 least a seven-day interval. When participants do not meet the criteria for restart after more  
41  
42  
43 than 8 days, the cycle stops at that time. If participants meet the starting criteria, they can start  
44  
45  
46 a new cycle. When participants do not meet the restart criteria after more than 42 days since  
47  
48  
49 the last day of taking S-1, they should stop the protocol treatment.  
50  
51

52 When restarting S-1 after withdrawal due to an adverse event, participants get a  
53  
54  
55 reduced dose of S-1. The daily dose of S-1 is reduced from 120 mg to 100 mg, from 100 mg  
56  
57  
58 to 80 mg, from 80 mg to 60 mg, or from 60 mg to 50 mg. Participants have two opportunities  
59  
60

1  
2  
3  
4 for reducing the drug. Participants taking 50 mg of S-1 should stop the protocol treatment.  
5  
6

7         If participants develop febrile neutropenia, they should be evaluated for infectious  
8  
9  
10 status, and antimicrobial agent or granulocyte colony stimulating factor (G-CSF)  
11  
12  
13 administered.  
14  
15

### 16 *Adherence*

17  
18  
19 Researchers provide patient compliance instructions, and confirm at each visit the remnant of  
20  
21  
22 drugs and whether participants have ingested the correct dose of S-1.  
23  
24  
25  
26  
27

### 28 **Concomitant drugs and therapy**

29  
30  
31 There are no concomitant drugs and therapy during this study.  
32  
33

### 34 **Outcomes**

#### 35 *Primary outcome*

36  
37  
38 The primary outcome is the completion rate of adjuvant chemotherapy. Completion is  
39  
40  
41 defined as participants who can finish a total of four cycles of S-1 adjuvant chemotherapy,  
42  
43  
44 regardless of relative performance index (RP: proportion of actual dose per expected dose)  
45  
46  
47  
48 after surgical resection of BTC.  
49  
50

#### 51 *Secondary outcomes*

52  
53  
54  
55 Secondary outcomes are as follows:  
56  
57

- 58 1) Post-operative cholangitis  
59  
60

- 1
- 2
- 3
- 4 2) Time to recurrence or distant metastasis
- 5
- 6
- 7 3) Changes in nutritional index from registration until the completion of chemotherapy
- 8
- 9
- 10 4) Changes in the lymphocyte blast transformation test induced by phytohemagglutinin
- 11
- 12
- 13 (PHA) and concanavalin A (Con-A) during adjuvant chemotherapy
- 14
- 15
- 16 5) Change in diamine oxidase serum activity (DAO) during adjuvant chemotherapy
- 17
- 18
- 19 6) All adverse events after medication. A modified version of The Common Terminology
- 20
- 21
- 22 Criteria for Adverse Events (CTCAE v4.0) is used to grade adverse events.
- 23
- 24

25 Prospective adverse events are as follows: coagulation disorder, lipid metabolism disorder,  
26  
27 abnormality of laboratory data, fatigue, fever, gastrointestinal disorders, skin and  
28  
29 subcutaneous tissue disorders, metabolism and nutrition disorders, nervous system disorders,  
30  
31 blood and lymphatic system disorders, eye disorders, infections and infestations, injury and  
32  
33 procedural complications.  
34  
35  
36  
37  
38  
39  
40  
41  
42

### 43 **Data analysis**

44  
45  
46 Participants who are recruited into this study and are administered one of the test drugs at  
47  
48 least once are included in the full analysis set (FAS). Participants who cannot provide  
49  
50 baseline data and have serious violations of protocol are not included in the FAS. The per  
51  
52 protocol set (PPS) is defined as participants in the FAS who comply with exclusion criteria,  
53  
54  
55 concomitant drugs, and concomitant therapy. An analysis of FAS is performed for each  
56  
57  
58  
59  
60



1  
2  
3  
4 outcome. Safety is analyzed in PPS. All analysis is performed with fixed data.  
5  
6  
7  
8  
9

#### 10 Primary outcome

11  
12  
13 The point estimate of the completion rate of S-1 and 95% confidence interval (CI) is  
14  
15  
16 calculated. Participants who complete S-1 are defined as participants who have performed  
17  
18  
19 four scheduled cycles of S-1, or have continued treatment for 168 days.  
20  
21  
22  
23  
24

#### 25 Secondary outcomes

26  
27  
28 Analyses of secondary outcomes take the form of simple descriptive statistics (e.g.,  
29  
30  
31 proportions and interquartile ranges (IQRs), means and standard deviations [SDs]) and where  
32  
33  
34 appropriate, point estimates of effect sizes (e.g., mean differences) and associated 95% CIs.  
35  
36

37  
38  
39 Recurrence-free survival curves are calculated using the Kaplan–Meier method, and 95% CIs  
40  
41  
42 are calculated.  
43  
44  
45

#### 46 Safety analysis

47  
48  
49 In the evaluation of the safety of the study, all adverse events due to the study are counted.  
50  
51

52  
53  
54 Severe adverse events are defined as the following three events: Grade 4 of a non-blood  
55  
56  
57 system disorder, early mortality within 30 days after the last treatment, or mortality causally  
58  
59  
60 related to the protocol treatment.

1  
2  
3  
4 Interim analysis is to be performed in this study. All statistical analyses are conducted  
5  
6  
7 using JMP software (version 13.0, SAS, Cray, NC, USA).  
8  
9  
10

### 11 12 13 **Data management**

14  
15  
16 Researchers make case report forms (CRF) for each participant. The modification of a CRF is  
17  
18 permitted only when it does not exceed the prescribed range and is not a burden to  
19  
20 participants. The principal investigator confirms and signs the CRF. CRFs are made at  
21  
22 registration (within two weeks), during a treatment period (each two cycles), at the end of  
23  
24 treatment (within 30 days), and in the follow-up period.  
25  
26  
27  
28  
29  
30  
31  
32  
33

### 34 **Data and safety monitoring**

35  
36  
37 Independent data and safety monitoring is conducted. The following materials are reviewed  
38  
39 every six months: informed consent obtained and signed, participant retention, study  
40  
41 implementation system, study safety and data, and study progress.  
42  
43  
44  
45  
46  
47  
48

### 49 **Confidentiality**

50  
51  
52 All study-related information is stored securely at the study site and identified by a coded  
53  
54 number only to maintain participant confidentiality. All participant information is stored in  
55  
56 locked file cabinets in areas with limited access. All records that contain names or other  
57  
58  
59  
60

1  
2  
3  
4 personal identifiers are stored separately from study records identified by code number. All  
5  
6  
7 local databases are secured with password-protected access systems. A participant's study  
8  
9  
10 information is not be released outside of the study without the written permission of the  
11  
12  
13 participant.

## 14 15 16 17 18 19 **ETHICS AND DISSEMINATION**

20  
21  
22 This study is conducted according to the declaration of Helsinki, Ethical Guidelines for  
23  
24  
25 Medical and Health Research Involving Human Subjects in Japan, and Management  
26  
27  
28 Guidelines of Conflict of Interest in our institution. The protocol has been approved by the  
29  
30  
31 Institutional Review Board of Kobe University Hospital (No 290086).

32  
33  
34 Researchers explain the study to potential participants using information sheets.

35  
36  
37 Patients are given the opportunity to ask questions and have enough time to consent to the  
38  
39  
40 study. Researchers obtain written consent from patients willing to participate in the study.  
41  
42  
43 Information sheets and consent forms are provided for all participants involved in the study.

44  
45  
46 The results of this study will be disseminated through academic conferences and peer-  
47  
48  
49 reviewed journals. All authors will review and approve the paper before publication. If there  
50  
51  
52 are several papers related to this study, the investigator will appoint each author.

## 53 54 55 56 57 58 **DISCUSSION**

1  
2  
3  
4 The biliary tract is divided into four anatomical components: intrahepatic bile duct,  
5  
6  
7 extrahepatic bile duct, gallbladder, and ampulla of Vater. Cancer staging is different for each  
8  
9  
10 origin, and the prognosis also differs. To select proper patients for this study, we decided that  
11  
12  
13 the indication criteria was Stage I or higher for intrahepatic cholangiocarcinoma and Stage  
14  
15  
16 II or higher for other BTCs according to a Japan Clinical Oncology Group (JCOG) 1202  
17  
18  
19 trial<sup>14</sup> which was conducted on the basis of the following data. The five-year survival rate in  
20  
21  
22 Stage I from a 2008 to 2013 nationwide survey in Japan<sup>15</sup> was 91% for gallbladder cancer  
23  
24  
25 and 92% for ampullary region cancer; a difference compared with other digestive organ  
26  
27  
28 cancers in Stage I was not found. Although the five-year survival rate is somewhat low,  
29  
30  
31 being 74% for perihilar bile duct cancer and 78% for distal bile duct cancer, cancer deaths for  
32  
33  
34 these diseases is not common. Potential reasons for the low ratios include perioperative  
35  
36  
37 deaths and late complications such as cholangitis. Therefore, since we had regarded that these  
38  
39  
40 patients get few benefits from adjuvant chemotherapy, in principle adjuvant chemotherapy  
41  
42  
43 was not performed for Stage I. In comparison, the 5-year survival rate of intrahepatic  
44  
45  
46 cholangiocarcinoma in patients with the tumor, less than 2 cm in diameter, that corresponds  
47  
48  
49 to Stage I is 36.3% in Japan's National Primary Liver Cancer Follow-up Survey (the 18th),  
50  
51  
52 which was worse than the same stage for other BTCs. Therefore adjuvant chemotherapy  
53  
54  
55 seems to be beneficial for patients of Stage I intrahepatic cholangiocarcinoma.  
56  
57  
58  
59  
60

1  
2  
3  
4           Though the target for adjuvant chemotherapy for BTC is still controversial, we have  
5  
6  
7 selected the relatively poor-prognosis group in BTC. Moreover, to align the patients post-  
8  
9  
10 surgical background, we have selected the type of surgical operation, which includes biliary  
11  
12  
13 reconstruction.

14  
15  
16           The most common reason for the interruption of adjuvant chemotherapy was an  
17  
18  
19 adverse event in BTC<sup>3</sup>. Seo et al.<sup>16</sup> reported that hypoalbuminemia (<3.5 mg/dL) was  
20  
21  
22 associated with adverse events greater than grade 3 in gastric cancer. Hypoalbuminemia is  
23  
24  
25 also a risk factor for the interruption of adjuvant chemotherapy in patients with pancreatic  
26  
27  
28 cancer<sup>17</sup>. The albumin level is one of the indications of nutritional status. According to a  
29  
30  
31 previous study, body weight loss is associated with the continuance of adjuvant  
32  
33  
34 chemotherapy<sup>6</sup>, and nutritional intervention, including omega-3 fatty acids, has an effect on  
35  
36  
37 several cancers<sup>7 8</sup>.

38  
39  
40           It is well known that chemotherapy including 5-fluorouracil (5-FU) causes  
41  
42  
43 gastrointestinal injury<sup>18</sup>. Five-fluorouracil also showed toxicity to helper T cells in mice,  
44  
45  
46 which seemed to cause immunosuppression<sup>19</sup>. These changes may result in BT<sup>20</sup>. From the  
47  
48  
49 viewpoint of immunity and infection, omega-3 fatty acids play a preventive role. Matsunaga  
50  
51  
52 et al. reported that a diet containing omega-3 fatty acid suppressed the thickening of mucosa,  
53  
54  
55 submucosa, and the muscular layer due to inflammation in mice compared with a control diet  
56  
57  
58 <sup>21</sup>. Moreover, omega-3 fatty acids inhibit infiltration of inflammatory cells into the muscularis  
59  
60

1  
2  
3  
4 mucosa<sup>19</sup>. In addition, the rate of BT and ileal change in pre- and postoperative feeding with  
5  
6  
7 omega-3 fatty acids in rats with a common bile duct ligation were the same as that of the  
8  
9  
10 control group, while BT and atrophy of intestinal mucosa in the postoperative feeding group  
11  
12  
13 increased compared to the control group<sup>22</sup>. From these reports, it is thought that the  
14  
15  
16 administration of omega-3 fatty acids from the start of chemotherapy, when intestinal  
17  
18  
19 mucosal disorder is not yet occurring, can keep the intestinal mucosa normal and prevent  
20  
21  
22 intestinal inflammation and the interruption of anticancer agents by infection.  
23  
24

25  
26 In addition to the nutritional aspect, omega-3 fatty acids have an anti-inflammatory  
27  
28 effect. After biliary reconstruction, it is easy for patients to experience cholangitis and stop  
29  
30 chemotherapy. Omega-3 fatty acids are known to calm acute inflammation by regulating  
31  
32 inflammatory cytokines<sup>9</sup>. Furthermore, *in vivo* experiments showed suppression of the  
33  
34 proliferation of cancer cells by inducing apoptosis in several cancers<sup>10 12 13</sup>.  
35  
36  
37  
38  
39

40  
41 In this study, we expect that omega-3 fatty acids will improve the completion rate of  
42  
43 adjuvant chemotherapy and lead to a good prognosis in patients with BTC. However, this  
44  
45 study may not be generalizable to other chemotherapy regimens since only S-1 is the target as  
46  
47  
48  
49 adjuvant chemotherapy.  
50

51  
52 **Acknowledgments** I would like to thank Dr. S Murakami and Kobe University Hospital  
53  
54  
55 Clinical & Translational Research Center for the support in setting up this research and  
56  
57  
58 preparing the manuscript.  
59  
60

1  
2  
3  
4 **Registry** This study is registered at UMIN Clinical Trials Registry (UMIN000031247) and  
5  
6  
7 Japan Registry of Clinical Trials (jRCTs051180007).  
8

9  
10 Registration Data Set: [https://upload.umin.ac.jp/cgi-open-](https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000035677)  
11  
12  
13 [bin/ctr/ctr\\_view.cgi?recptno=R000035677](https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000035677)  
14

15  
16 Registration Data Set: <https://jrct.niph.go.jp/detail/349>  
17

18  
19 **Contributors** KU designed the study, and wrote the initial draft of the manuscript.  
20

21  
22 TA and TF contributed to analysis and interpretation of data, and assisted in the preparation  
23  
24 of the manuscript. DT, MA and YH contributed to analysis and interpretation of data.  
25

26  
27 MA, HM, SK, KK, ST, MT, HT and MK contributed to collect the clinical data.  
28

29  
30 All authors approved the final version of the manuscript, and agree to be accountable for all  
31  
32 aspects of the work in ensuring that questions related to the accuracy or integrity of any part  
33  
34 of the work are appropriately investigated and resolved.  
35  
36  
37  
38

39  
40 **Funding** This study has received no specific grant from any funding agency in the public,  
41  
42 commercial or not-for-profit sectors.  
43  
44

45  
46 **Competing interests** None declared.  
47

48  
49 **Patient consent** Obtained  
50

51  
52 **Patient and Public Involvement** We did not involve patients or the public in our work  
53

54  
55 **Ethics approval** Kobe University Clinical Research Ethical Committee  
56

57  
58 **Issue date:** September 20, 2018  
59

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Protocol amendment number: 1.4**

For peer review only



Table 1 Inclusion and exclusion criteria for patients

<b>Inclusion criteria</b>
<p>1) Pathologically diagnosed as adenocarcinoma (in case of a combined cancer, adenocarcinoma is dominant)</p> <p>2) UICC stage is as follows:</p> <p style="padding-left: 40px;">Stage I or higher in intrahepatic cholangiocarcinoma</p> <p style="padding-left: 40px;">Stage II or higher in perihilar bile duct cancer, distal bile duct cancer, gallbladder cancer and ampulla region cancer</p> <p>3) age 20 – 80 years or younger</p> <p>4) ECOG performance status is 0 or 1</p> <p>5) CT and MRI show no metastases, and moderate or less pleural effusion* or ascites**</p> <p>6) Performed pancreaticoduodenectomy, hepatectomy, bile duct resection, caudal lobectomy and/or cholecystectomy, with D1 or more extensive lymphadenectomy***</p> <p>7) No history of any prior chemotherapy or radiation therapy</p> <p>8) 14 to 70 days from surgical resection</p> <p>9) Good oral intake</p> <p>10) No watery diarrhea</p> <p>Meets all the following laboratory data values within 14 days before registration</p> <p>a) neutrophils <math>\geq 1,200/\text{mm}^3</math></p> <p>b) platelets <math>\geq 10,000/\text{mm}^3</math></p> <p>c) hemoglobin <math>\geq 8.0\text{g/L}</math></p> <p>d) total bilirubin <math>\leq 2.0\text{ mg/dL}</math></p> <p>e) AST <math>\leq 100\text{ IU/L}</math></p> <p>f) ALT <math>\leq 100\text{ IU/L}</math></p> <p>g) serum creatinine <math>\leq 1.2\text{ mg/dL}</math></p> <p>h) creatinine clearance (CC) <math>\geq 40\text{ mL/min}</math> (CC calculated by Cockcroft–Gault Equation)</p> <p>11) Written informed consent</p>
<b>Exclusion criteria</b>
<p>1) Allergic predisposition or drug hypersensitivity</p> <p>2) Double or multiple cancers diagnosed or treated in the past five years. (except for carcinoma <i>in situ</i>)</p> <p>3) Active infectious disease (except for virus hepatitis)</p> <p>4) Fever above 38°C</p>

- 5) Current pregnancy, breastfeeding, planning to become pregnant during the study
- 6) Psychological disease and/or symptoms
- 7) Severe liver or renal dysfunction
- 8) Uncontrollable hypertension or diabetes mellitus
- 9) Uncontrollable ischemic heart disease:
  - developing angina or worsening within three weeks
  - developing myocardial infarction within six months
- 10) Taking flucytosine, phenytoin, or warfarin potassium
- 11) Interstitial pneumonitis, pulmonary fibrosis, and pulmonary emphysema
- 12) Taking omega-3 fatty acid formulations
- 13) Considered unsuitable by their attending physician

CT, computed tomography; MRI, magnetic resonance imaging; UICC, Union for International Cancer Control; ECOG, Eastern Cooperative Oncology Group; AST, aspartate aminotransferase; ALT, alanine aminotransferase

\*Moderate plural effusion is defined as effusion occupying one third of the lung field by chest X-ray. \*\*Moderate ascites is defined as ascites within the pelvic cavity. \*\*\*In the case of intrahepatic cholangiocarcinoma without invasion to the hepatic portal region, lymphadenectomy is not necessary.



1  
2  
3  
4 operation time). Screening tests are general status, blood test, urinary test, computed  
5  
6  
7 tomography and electrocardiogram. General status includes blood pressure, body temperature,  
8  
9  
10 pulse rate and respiratory rate. Blood test includes complete blood count, differential count of  
11  
12  
13 leukocytes, total protein, albumin, total bilirubin, creatinine, aspartate transaminase, alanine  
14  
15  
16 aminotransferase, alkaline phosphatase, lactate dehydrogenase, Na, K, total cholesterol, high-  
17  
18  
19 density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and  
20  
21  
22 triglyceride. ConA, concanavalin A; PHA, phytohemagglutinin; DAO, diamine oxidase  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 3 Dose of S-1

	Dose of S-1	
Body surface area (m <sup>2</sup> )	50 mL/min ≤ Ccr < 60 mL/min	60 mL/min ≤ Ccr
under 1.25	60 mg/day	80 mg/day
1.25 to 1.5	80 mg/day	100 mg/day
over 1.5	100 mg/day	120 mg/day

Ccr, creatinine clearance

Figure legend

Figure 1 Summary of study.

## References

1. Miyakawa S, Ishihara S, Horiguchi A, et al. BTC treatment: 5,584 results from the BTC Statistics Registry from 1998 to 2004 in Japan. *J Hepatobiliary Pancreat Surg* 2009;16(1):1-7. doi: 10.1007/s00534-008-0015-0 [published Online First: 2008/12/27]
2. Waseem D, Tushar P. Intrahepatic, perihilar and distal cholangiocarcinoma: Management and outcomes. *Ann Hepatol* 2017;16(1):133-39. doi: 10.5604/16652681.1226927 [published Online First: 2017/01/05]
3. Nakachi K, Konishi M, Ikeda M, et al. Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with BTC. *Int J Clin Oncol* 2018 doi:

- 1  
2  
3  
4 10.1007/s10147-018-1283-6 [published Online First: 2018/05/01]  
5  
6  
7 4. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer  
8  
9  
10 with S-1, an oral fluoropyrimidine. *N Engl J Med* 2007;357(18):1810-20. doi:  
11  
12 10.1056/NEJMoa072252 [published Online First: 2007/11/06]  
13  
14  
15  
16 5. Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine  
17  
18 for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority  
19  
20 trial (JASPAC 01). *Lancet* 2016;388(10041):248-57. doi: 10.1016/S0140-  
21  
22 6736(16)30583-9 [published Online First: 2016/06/07]  
23  
24  
25  
26  
27  
28 6. Aoyama T, Yoshikawa T, Shirai J, et al. Body weight loss after surgery is an independent  
29  
30 risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. *Ann*  
31  
32 *Surg Oncol* 2013;20(6):2000-6. doi: 10.1245/s10434-012-2776-6 [published Online  
33  
34 First: 2012/12/18]  
35  
36  
37  
38  
39  
40 7. Aoyama T, Hayashi T, Fujikawa H, et al. [Effect of enteral nutrition enriched with  
41  
42 eicosapentaenoic acid on body weight loss and compliance with S-1 adjuvant  
43  
44 chemotherapy after gastric cancer surgery]. *Gan To Kagaku Ryoho*  
45  
46 2013;40(12):2289-91. [published Online First: 2014/01/08]  
47  
48  
49  
50  
51  
52 8. Murphy RA, Mourtzakis M, Chu QS, et al. Nutritional intervention with fish oil provides a  
53  
54 benefit over standard of care for weight and skeletal muscle mass in patients with  
55  
56 nonsmall cell lung cancer receiving chemotherapy. *Cancer* 2011;117(8):1775-82.  
57  
58  
59  
60

- 1  
2  
3  
4 doi: 10.1002/cncr.25709 [published Online First: 2011/03/02]  
5  
6  
7 9. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. *Nature*  
8  
9  
10 2014;510(7503):92-101. doi: 10.1038/nature13479 [published Online First:  
11  
12 2014/06/06]  
13  
14  
15  
16 10. Cao W, Ma Z, Rasenick MM, et al. N-3 poly-unsaturated fatty acids shift estrogen  
17  
18 signaling to inhibit human breast cancer cell growth. *PLoS One* 2012;7(12):e52838.  
19  
20  
21  
22 doi: 10.1371/journal.pone.0052838 [published Online First: 2013/01/04]  
23  
24  
25 11. Chagas TR, Borges DS, de Oliveira PF, et al. Oral fish oil positively influences  
26  
27 nutritional-inflammatory risk in patients with haematological malignancies during  
28  
29 chemotherapy with an impact on long-term survival: a randomised clinical trial. *J*  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41 12. Mizoguchi K, Ishiguro H, Kimura M, et al. Induction of apoptosis by eicosapentaenoic  
42  
43 acid in esophageal squamous cell carcinoma. *Anticancer Res* 2014;34(12):7145-9.  
44  
45  
46 [published Online First: 2014/12/17]  
47  
48  
49 13. Shirota T, Haji S, Yamasaki M, et al. Apoptosis in human pancreatic cancer cells induced  
50  
51 by eicosapentaenoic acid. *Nutrition* 2005;21(10):1010-7. doi:  
52  
53  
54  
55 10.1016/j.nut.2004.12.013 [published Online First: 2005/09/15]  
56  
57  
58 14. Nakachi K, Konishi M, Ikeda M et al. A randomized Phase III trial of adjuvant S-1  
59  
60

- 1  
2  
3  
4 therapy vs. observation alone in resected BTC: Japan Clinical Oncology Group Study  
5  
6  
7 (JCOG1202, ASCOT) Japanese Journal of Clinical Oncology, 2018, 48(4) 392–395  
8  
9
- 10 15. Ishihara S, Horiguchi A, Miyakawa S et al. BTC registry in Japan from 2008 to 2013  
11  
12  
13 J Hepatobiliary pancreato Sci 2016 ;Mar23(3):149-57  
14  
15
- 16 16. Seo SH, Kim SE, Kang YK, et al. Association of nutritional status-related indices and  
17  
18  
19 chemotherapy-induced adverse events in gastric cancer patients. *BMC Cancer*  
20  
21  
22 2016;16(1):900. doi: 10.1186/s12885-016-2934-5 [published Online First:  
23  
24  
25 2016/11/20]  
26  
27
- 28 17. Matsumoto I, Tanaka M, Shirakawa S, et al. Postoperative Serum Albumin Level is a  
29  
30  
31 Marker of Incomplete Adjuvant Chemotherapy in Patients with Pancreatic Ductal  
32  
33  
34 Adenocarcinoma. *Ann Surg Oncol* 2015;22(7):2408-15. doi: 10.1245/s10434-014-  
35  
36  
37 4280-7 [published Online First: 2014/12/10]  
38  
39
- 40 18. Murakami M, Sato N, Tashiro K, et al. Effects of caloric intake on intestinal mucosal  
41  
42  
43 morphology and immune cells in rats treated with 5-Fluorouracil. *J Clin Biochem*  
44  
45  
46 *Nutr* 2009;45(1):74-81. doi: 10.3164/jcbrn.08-264 [published Online First:  
47  
48  
49 2009/07/11]  
50  
51
- 52 19. Merluzzi VJ, Last-Barney K, Susskind BM, et al. Recovery of humoral and cellular  
53  
54  
55 immunity by soluble mediators after 5-fluorouracil-induced immunosuppression. *Clin*  
56  
57  
58 *Exp Immunol* 1982;50(2):318-26. [published Online First: 1982/11/01]  
59  
60



- 1  
2  
3  
4 20. Tsuji E, Hiki N, Nomura S, et al. Simultaneous onset of acute inflammatory response,  
5  
6  
7 sepsis-like symptoms and intestinal mucosal injury after cancer chemotherapy. *Int J*  
8  
9  
10 *Cancer* 2003;107(2):303-8. doi: 10.1002/ijc.11196 [published Online First:  
11  
12  
13 2003/09/02]  
14  
15  
16 21. Matsunaga H, Hokari R, Kurihara C, et al. Omega-3 polyunsaturated fatty acids  
17  
18  
19 ameliorate the severity of ileitis in the senescence accelerated mice (SAM)P1/Yit  
20  
21  
22 mice model. *Clin Exp Immunol* 2009;158(3):325-33. doi: 10.1111/j.1365-  
23  
24  
25 2249.2009.04020.x [published Online First: 2009/10/02]  
26  
27  
28 22. Zulfikaroglu B, Zulfikaroglu E, Ozmen MM, et al. The effect of immunonutrition on  
29  
30  
31 bacterial translocation, and intestinal villus atrophy in experimental obstructive  
32  
33  
34 jaundice. *Clin Nutr* 2003;22(3):277-81. [published Online First: 2003/05/27]  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure1. Summary of study

Summary of study  
190x275mm (96 x 96 DPI)

# Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	<a href="#">#1</a>	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	<a href="#">#2a</a>	Trial identifier and registry name. If not yet registered, name of intended registry	18
Trial registration: data set	<a href="#">#2b</a>	All items from the World Health Organization Trial Registration Data Set	18
Protocol version	<a href="#">#3</a>	Date and version identifier	18
Funding	<a href="#">#4</a>	Sources and types of financial, material, and other support	18
Roles and responsibilities: contributorship	<a href="#">#5a</a>	Names, affiliations, and roles of protocol contributors	18
Roles and responsibilities:	<a href="#">#5b</a>	Name and contact information for the trial sponsor	N/A

1	sponsor contact			
2	information			
3				
4	Roles and	<a href="#">#5c</a>	Role of study sponsor and funders, if any, in study design;	N/A
5	responsibilities:		collection, management, analysis, and interpretation of data;	
6	sponsor and funder		writing of the report; and the decision to submit the report for	
7			publication, including whether they will have ultimate authority	
8			over any of these activities	
9				
10				
11				
12	Roles and	<a href="#">#5d</a>	Composition, roles, and responsibilities of the coordinating	13-14
13	responsibilities:		centre, steering committee, endpoint adjudication committee,	
14	committees		data management team, and other individuals or groups	
15			overseeing the trial, if applicable (see Item 21a for data	
16			monitoring committee)	
17				
18				
19				
20	Background and	<a href="#">#6a</a>	Description of research question and justification for undertaking	5
21	rationale		the trial, including summary of relevant studies (published and	
22			unpublished) examining benefits and harms for each intervention	
23				
24				
25				
26	Background and	<a href="#">#6b</a>	Explanation for choice of comparators	7
27	rationale: choice of			
28	comparators			
29				
30				
31	Objectives	<a href="#">#7</a>	Specific objectives or hypotheses	5-6
32				
33				
34	Trial design	<a href="#">#8</a>	Description of trial design including type of trial (eg, parallel	6-7
35			group, crossover, factorial, single group), allocation ratio, and	
36			framework (eg, superiority, equivalence, non-inferiority,	
37			exploratory)	
38				
39				
40	Study setting	<a href="#">#9</a>	Description of study settings (eg, community clinic, academic	8-9
41			hospital) and list of countries where data will be collected.	
42			Reference to where list of study sites can be obtained	
43				
44				
45				
46	Eligibility criteria	<a href="#">#10</a>	Inclusion and exclusion criteria for participants. If applicable,	8
47			eligibility criteria for study centres and individuals who will	
48			perform the interventions (eg, surgeons, psychotherapists)	
49				
50				
51	Interventions:	<a href="#">#11a</a>	Interventions for each group with sufficient detail to allow	9-10
52	description		replication, including how and when they will be administered	
53				
54				
55	Interventions:	<a href="#">#11b</a>	Criteria for discontinuing or modifying allocated interventions	9-10
56	modifications		for a given trial participant (eg, drug dose change in response to	
57			harms, participant request, or improving / worsening disease)	
58				
59				
60				

1	Interventions:	<a href="#">#11c</a>	Strategies to improve adherence to intervention protocols, and	11
2	adherence		any procedures for monitoring adherence (eg, drug tablet return;	
3			laboratory tests)	
4				
5				
6	Interventions:	<a href="#">#11d</a>	Relevant concomitant care and interventions that are permitted or	11
7	concomitant care		prohibited during the trial	
8				
9				
10	Outcomes	<a href="#">#12</a>	Primary, secondary, and other outcomes, including the specific	11-12
11			measurement variable (eg, systolic blood pressure), analysis	
12			metric (eg, change from baseline, final value, time to event),	
13			method of aggregation (eg, median, proportion), and time point	
14			for each outcome. Explanation of the clinical relevance of chosen	
15			efficacy and harm outcomes is strongly recommended	
16				
17				
18				
19				
20	Participant timeline	<a href="#">#13</a>	Time schedule of enrolment, interventions (including any run-ins	8
21			and washouts), assessments, and visits for participants. A	
22			schematic diagram is highly recommended (see Figure)	
23				
24				
25	Sample size	<a href="#">#14</a>	Estimated number of participants needed to achieve study	7
26			objectives and how it was determined, including clinical and	
27			statistical assumptions supporting any sample size calculations	
28				
29				
30	Recruitment	<a href="#">#15</a>	Strategies for achieving adequate participant enrolment to reach	8
31			target sample size	
32				
33				
34	Allocation: sequence	<a href="#">#16a</a>	Method of generating the allocation sequence (eg, computer-	NA
35	generation		generated random numbers), and list of any factors for	
36			stratification. To reduce predictability of a random sequence,	this study
37			details of any planned restriction (eg, blocking) should be	is single-
38			provided in a separate document that is unavailable to those who	arm
39			enrol participants or assign interventions	
40				
41				
42				
43				
44	Allocation	<a href="#">#16b</a>	Mechanism of implementing the allocation sequence (eg, central	NA
45	concealment		telephone; sequentially numbered, opaque, sealed envelopes),	
46	mechanism		describing any steps to conceal the sequence until interventions	this study
47			are assigned	is single-
48				arm
49				
50				
51	Allocation:	<a href="#">#16c</a>	Who will generate the allocation sequence, who will enrol	NA
52	implementation		participants, and who will assign participants to interventions	
53				this study
54				is single-
55				arm
56				
57				
58				
59				
60				

1	Blinding (masking)	<a href="#">#17a</a>	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	NA this study is single- arm
2				
3				
4				
5				
6				
7				
8	Blinding (masking):	<a href="#">#17b</a>	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	NA this study is single- arm
9	emergency			
10	unblinding			
11				
12				
13				
14				
15				
16	Data collection plan	<a href="#">#18a</a>	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	13
17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27	Data collection plan:	<a href="#">#18b</a>	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	13
28	retention			
29				
30				
31				
32				
33	Data management	<a href="#">#19</a>	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	13-14
34				
35				
36				
37				
38				
39	Statistics: outcomes	<a href="#">#20a</a>	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	12-13
40				
41				
42				
43				
44				
45	Statistics: additional	<a href="#">#20b</a>	Methods for any additional analyses (eg, subgroup and adjusted analyses)	12-13
46	analyses			
47				
48				
49	Statistics: analysis	<a href="#">#20c</a>	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	13
50	population and			
51	missing data			
52				
53				
54	Data monitoring:	<a href="#">#21a</a>	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found,	14
55	formal committee			
56				
57				
58				
59				
60				

if not in the protocol. Alternatively, an explanation of why a DMC is not needed

1			
2			
3			
4	Data monitoring:	<a href="#">#21b</a>	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial
5	interim analysis		
6			
7			
8			
9			
10			
11	Harms	<a href="#">#22</a>	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct
12			
13			
14			
15			
16	Auditing	<a href="#">#23</a>	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor
17			
18			
19			
20			
21	Research ethics approval	<a href="#">#24</a>	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval
22			
23			
24			
25	Protocol amendments	<a href="#">#25</a>	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)
26			
27			
28			
29			
30			
31			
32	Consent or assent	<a href="#">#26a</a>	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)
33			
34			
35			
36	Consent or assent: ancillary studies	<a href="#">#26b</a>	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable
37			
38			
39			
40			
41	Confidentiality	<a href="#">#27</a>	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial
42			
43			
44			
45			
46	Declaration of interests	<a href="#">#28</a>	Financial and other competing interests for principal investigators for the overall trial and each study site
47			
48			
49			
50	Data access	<a href="#">#29</a>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators
51			
52			
53			
54			
55			
56	Ancillary and post trial care	<a href="#">#30</a>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation
57			
58			
59			
60			

1	Dissemination	<a href="#">#31a</a>	Plans for investigators and sponsor to communicate trial results	15
2	policy: trial results		to participants, healthcare professionals, the public, and other	
3			relevant groups (eg, via publication, reporting in results	
4			databases, or other data sharing arrangements), including any	
5			publication restrictions	
6				
7				
8				
9	Dissemination	<a href="#">#31b</a>	Authorship eligibility guidelines and any intended use of	15
10	policy: authorship		professional writers	
11				
12				
13	Dissemination	<a href="#">#31c</a>	Plans, if any, for granting public access to the full protocol,	N/A
14	policy: reproducible		participant-level dataset, and statistical code	
15	research			
16				
17				
18	Informed consent	<a href="#">#32</a>	Model consent form and other related documentation given to	N/A
19	materials		participants and authorised surrogates	
20				
21				only in
22				japanese
23				
24	Biological specimens	<a href="#">#33</a>	Plans for collection, laboratory evaluation, and storage of	N/A
25			biological specimens for genetic or molecular analysis in the	
26			current trial and for future use in ancillary studies, if applicable	
27				
28				
29				

30 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND  
 31 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR](#)  
 32 [Network](#) in collaboration with [Penelope.ai](#)  
 33  
 34  
 35  
 36  
 37  
 38  
 39  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60